[go: up one dir, main page]

RS54993B1 - Terapijski režimi - Google Patents

Terapijski režimi

Info

Publication number
RS54993B1
RS54993B1 RS20160609A RSP20160609A RS54993B1 RS 54993 B1 RS54993 B1 RS 54993B1 RS 20160609 A RS20160609 A RS 20160609A RS P20160609 A RSP20160609 A RS P20160609A RS 54993 B1 RS54993 B1 RS 54993B1
Authority
RS
Serbia
Prior art keywords
therapeutic regimens
regimens
therapeutic
Prior art date
Application number
RS20160609A
Other languages
English (en)
Inventor
Louis O'dea
C Richard Lyttle
Jonathan Guerriero
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Health Inc filed Critical Radius Health Inc
Publication of RS54993B1 publication Critical patent/RS54993B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20160609A 2010-05-12 2011-05-12 Terapijski režimi RS54993B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33409510P 2010-05-12 2010-05-12
PCT/US2011/036311 WO2011143469A1 (en) 2010-05-12 2011-05-12 Therapeutic regimens
EP11781299.0A EP2568806B1 (en) 2010-05-12 2011-05-12 Therapeutic regimens

Publications (1)

Publication Number Publication Date
RS54993B1 true RS54993B1 (sr) 2016-11-30

Family

ID=44914714

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160609A RS54993B1 (sr) 2010-05-12 2011-05-12 Terapijski režimi

Country Status (17)

Country Link
US (2) US20130053448A1 (sr)
EP (2) EP3106159A1 (sr)
CA (1) CA2799183A1 (sr)
CY (1) CY1117893T1 (sr)
DK (1) DK2568806T3 (sr)
ES (1) ES2585884T3 (sr)
HR (1) HRP20160929T1 (sr)
HU (1) HUE030072T2 (sr)
LT (1) LT2568806T (sr)
ME (1) ME02474B (sr)
MX (1) MX342898B (sr)
PL (1) PL2568806T3 (sr)
PT (1) PT2568806T (sr)
RS (1) RS54993B1 (sr)
SI (1) SI2568806T1 (sr)
SM (1) SMT201600263B (sr)
WO (1) WO2011143469A1 (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
JP5965909B2 (ja) 2010-09-28 2016-08-10 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
SG11201811225RA (en) 2016-06-22 2019-01-30 Radius Health Inc Ar+ breast cancer treatment methods
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
AU2019297421B2 (en) 2018-07-04 2024-08-29 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL
WO2024252263A1 (en) * 2023-06-05 2024-12-12 Berlin-Chemie Ag Solid elacestrant dihydrochloride compositions, methods of making the same, and methods of treatment using the same

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1547758A (en) 1975-07-29 1979-06-27 Shell Int Research Herbicidal composition
JPH01261381A (ja) 1988-04-12 1989-10-18 Nippon Soda Co Ltd オキサ（チア）ジアゾール誘導体、その製造方法及び殺ダニ剤
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
UA51652C2 (uk) 1995-06-08 2002-12-16 Новартіс Аг Спосіб гідрування імінів
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
ATE209207T1 (de) 1996-06-27 2001-12-15 Ligand Pharm Inc Androgen rezeptor modulator verbindungen und verfahren
US20090264534A1 (en) 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
FR2770842B1 (fr) 1997-11-13 1999-12-17 Oreal Nouveaux composes derives de n-aryl 2-hydroxy alkylamides
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6159959A (en) 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
WO2001036039A2 (en) 1999-11-17 2001-05-25 Novartis Ag Iontophoretic transdermal delivery of peptides
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
KR20020075388A (ko) 1999-12-30 2002-10-04 시그널 파머슈티컬스 인크 에스트로겐 수용체의 조절 화합물 및 조절 방법
KR20020073566A (ko) 2000-01-28 2002-09-27 앙도르쉐르슈 인코포레이티드 에스트로겐과 배합된 선택적인 에스트로겐 수용체 조절자
IL152719A0 (en) 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
DE60127277T2 (de) 2000-08-03 2007-11-29 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
DK1491524T3 (da) 2000-08-24 2009-05-04 Univ Tennessee Res Foundation Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
DE60138407D1 (de) 2000-10-26 2009-05-28 Alza Corp Transdermales arzneistoffverabreichungssytem mit beschichteten mikrovorsprüngen
US6670386B2 (en) 2001-07-31 2003-12-30 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2003015761A1 (en) 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
US6933321B2 (en) 2002-02-15 2005-08-23 Endorecherche, Inc. Antiandrogenic biphenyls
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
PT1501819E (pt) 2002-04-24 2010-11-11 Merck Sharp & Dohme Moduladores dos receptores de estrogéneo
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
EP1551438A2 (en) 2002-06-13 2005-07-13 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
PT1557411E (pt) 2002-07-12 2012-11-22 Astellas Pharma Inc Derivado de n-fenil-(2r,5s)dimetilpiperazina
AU2003254993A1 (en) 2002-08-12 2004-03-03 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
UA79504C2 (en) 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
JP4500689B2 (ja) 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的エストロゲン受容体モジュレーター
WO2004080377A2 (en) 2003-03-11 2004-09-23 Neurosearch A/S Kcnq channel modulating compounds and their pharmaceutical use
US20060142387A1 (en) 2003-06-10 2006-06-29 Rodolfo Cadilla Chemical compounds
EP1654221A2 (en) 2003-06-10 2006-05-10 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
KR20060038407A (ko) 2003-06-30 2006-05-03 알자 코포레이션 비휘발성 반대이온을 포함하는 코팅된 미세돌출부용 제제
EP1643978A1 (en) * 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
CA2537660A1 (en) 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US7097631B2 (en) 2003-10-31 2006-08-29 Alza Corporation Self-actuating applicator for microprojection array
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
AU2004292954A1 (en) 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
CA2545048A1 (en) 2003-11-20 2005-06-02 Warner-Lambert Company Llc Androgen receptor modulators
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
CN1930181A (zh) 2004-01-07 2007-03-14 恩多研究公司 螺旋12定向的甾族药品
BRPI0506721A (pt) 2004-01-22 2007-05-02 Lilly Co Eli composto ou um sal de adição de ácido do mesmo
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
ES2523017T3 (es) 2004-03-03 2014-11-20 Glaxosmithkline Llc Derivados de anilina como moduladores selectivos de los receptores de andrógenos
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
JP2007223901A (ja) 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
AU2005232619B2 (en) 2004-04-08 2008-07-24 Merck Sharp & Dohme Corp. 17 beta-acetamide-4-azasteroids as androgen receptor modulators
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
CA2564952A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
EP1747193A1 (en) 2004-05-11 2007-01-31 Pfizer Products Incorporated Benzonitrile derivatives to treat musculoskeletal frailty
BRPI0509788A (pt) 2004-05-13 2007-10-23 Alza Corp aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides
CA2566942A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
MXPA06013924A (es) 2004-05-29 2007-07-18 7Tm Pharma As Acidos tiazolaceticos sustituidos como ligandos crth2.
AU2005251781C1 (en) 2004-06-07 2008-02-21 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
ES2422204T3 (es) 2004-09-10 2013-09-09 Janssen Pharmaceutica Nv Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
US7338973B2 (en) 2004-09-20 2008-03-04 Janssen Pharmaceutica N.V. Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
EP1805147B1 (en) 2004-09-30 2014-08-13 Janssen Pharmaceutica NV Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
WO2006044707A1 (en) 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
CN101052398A (zh) 2004-10-29 2007-10-10 默克公司 作为雄激素受体调节剂的n－(吡啶－3－基)－2－苯基丁酰胺
CN104803916B (zh) 2004-11-16 2017-08-11 詹森药业有限公司 用作选择性雄激素受体调节剂(sarms)的杂环衍生物
EP1848498A4 (en) 2004-11-18 2009-12-16 Transpharma Medical Ltd ASSOCIATED MICRO-CHANNEL PRODUCTION AND IONTOPHORESIS FOR TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
ZA200705458B (en) 2005-01-10 2008-12-31 Acadia Pharm Inc Aminophenyl derivatives as selective androgen receptor modulators
JP2008536868A (ja) 2005-04-15 2008-09-11 スミスクライン・ビーチャム・コーポレイション シアノアリールアミン
DE602006003432D1 (de) 2005-05-13 2008-12-11 Lilly Co Eli Latoren des androgenrezeptors
US20090170907A1 (en) 2005-06-06 2009-07-02 Smithkline Beecham Corporation Chemical Compounds
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US7935722B2 (en) 2005-06-24 2011-05-03 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators
WO2007005887A2 (en) 2005-07-01 2007-01-11 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds, compositions and uses thereof
EP1911743B8 (en) 2005-08-01 2013-01-16 Takeda Pharmaceutical Company Limited Cyclic amine compound
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
US7776859B2 (en) 2005-10-14 2010-08-17 Bristol-Myers Squibb Company Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function
US8900180B2 (en) 2005-11-18 2014-12-02 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
TW200730505A (en) 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
EP1981547B1 (en) 2005-12-28 2015-09-30 Alza Corporation Stable therapeutic formulations
SI1984343T1 (sl) 2006-01-24 2013-05-31 Janssen Pharmaceutica N.V. 2-substituirani benzimidazoli kot selektivni modulatorji androgenskih receptorjev (sarms)
RU2435756C2 (ru) 2006-03-03 2011-12-10 Орион Корпорейшн Избирательные андрогенные рецепторные модуляторы
CN101466393A (zh) 2006-03-15 2009-06-24 阿尔扎公司 用于经皮递送甲状旁腺激素药剂以治疗骨质减少的方法
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
CA2656067C (en) * 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EA031888B1 (ru) 2006-07-12 2019-03-29 Юниверсити Оф Теннесси Рисерч Фаундейшн Способы применения замещенных ациланилидов
EP2040709A2 (en) 2006-07-19 2009-04-01 Osurf Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
KR101202240B1 (ko) 2006-08-24 2012-11-16 유니버시티 오브 테네시 리서치 파운데이션 치환된 아실아닐리드 및 그의 사용 방법
ES2452343T3 (es) 2006-09-29 2014-04-01 Glaxosmithkline Llc Compuestos de indol sustituidos
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
CN102274492B (zh) 2006-10-03 2014-11-26 半径健康公司 骨合成代谢蛋白质的药物递送方法
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2008128100A1 (en) 2007-04-13 2008-10-23 The Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
ES2820335T3 (es) 2007-04-16 2021-04-20 Corium Inc Matrices de microagujas coladas con disolvente que contienen agente activo
ES2406685T3 (es) 2007-08-07 2013-06-07 Takeda Pharmaceutical Company Limited Derivados de pirrolidin-2-ona como moduladores de los receptores de andrógenos
US20090117158A1 (en) 2007-10-23 2009-05-07 Mahmoud Ameri Transdermal sustained release drug delivery
US20110105554A1 (en) 2007-11-21 2011-05-05 Kinaris Biomedicals Gmbh Means for treating myosin-related diseases
KR20100099742A (ko) 2007-12-21 2010-09-13 아스트라제네카 아베 안드로겐 수용체 관련 병태의 치료에서 사용하기 위한 이환식 유도체
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
CA2716320C (en) 2008-02-22 2014-01-28 Radius Health, Inc. Selective androgen receptor modulators
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
WO2009137104A1 (en) * 2008-05-09 2009-11-12 Radius Health, Inc. Combination therapy for breastcancer comprising an antiestrogenic agent
MX2010012436A (es) 2008-05-16 2010-12-06 Lilly Co Eli Moduladores de receptor de androgenos tetrahidrociclopenta [b] indol.
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
CN102202682B (zh) 2008-11-04 2015-08-19 Aska制药株式会社 含促卵泡激素的水性组合物
CN102264429B (zh) 2008-12-26 2014-01-08 久光制药株式会社 微针装置
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
EP3244394A1 (en) 2009-10-16 2017-11-15 Semiconductor Energy Laboratory Co., Ltd. Liquid crystal display device and electronic apparatus having the same
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
ES2719595T3 (es) 2010-05-04 2019-07-11 Corium Int Inc Método y dispositivo para la administración transdérmica de la hormona paratiroidea usando una matriz de microproyección
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
CN102917722B (zh) 2010-05-28 2018-05-22 3M创新有限公司 用于涂布微针阵列的水性制剂
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
JP5965909B2 (ja) 2010-09-28 2016-08-10 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
JP6033280B2 (ja) 2011-04-22 2016-11-30 ラジウス ヘルス，インコーポレイテッド ＰＴＨ、ＰＴＨｒＰ、および関連ペプチドの薬剤送達方法
WO2013082427A1 (en) 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same

Also Published As

Publication number Publication date
EP3106159A1 (en) 2016-12-21
ME02474B (me) 2017-02-20
EP2568806B1 (en) 2016-05-11
HRP20160929T1 (hr) 2016-10-07
SMT201600263B (it) 2016-08-31
DK2568806T3 (en) 2016-08-15
US9555014B2 (en) 2017-01-31
LT2568806T (lt) 2016-09-26
MX2012013014A (es) 2013-02-27
ES2585884T3 (es) 2016-10-10
EP2568806A4 (en) 2013-09-11
US20130053448A1 (en) 2013-02-28
US20160022608A1 (en) 2016-01-28
HUE030072T2 (en) 2017-04-28
SI2568806T1 (sl) 2016-09-30
CA2799183A1 (en) 2011-11-17
PL2568806T3 (pl) 2017-03-31
EP2568806A1 (en) 2013-03-20
PT2568806T (pt) 2016-08-05
MX342898B (es) 2016-10-18
CY1117893T1 (el) 2017-05-17
WO2011143469A8 (en) 2012-01-19
WO2011143469A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
HRP20181615T1 (hr) Terapijsko sredstvo koje izaziva citotoksičnost
HRP20181531T1 (hr) Protuvirusna terapija
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
GB201106527D0 (en) Therapeutic apparatus
GB201004020D0 (en) New therapeutic use
HRP20160929T1 (hr) Terapijski režimi
EP2605786A4 (en) THERAPEUTIC PEPTIDES
EP2595594A4 (en) MASSAGER
GB201005394D0 (en) Therapy
ZA201307760B (en) Treatment regimens
GB201016864D0 (en) Therapeutic methods
GB201010500D0 (en) Therapeutic conjugates
EP2629766A4 (en) COMBINATION THERAPY
GB201010582D0 (en) Therapeutic agents
GB201014963D0 (en) Therapeutic agents
GB201012100D0 (en) Therapeutic agents
GB201012102D0 (en) Therapeutic agents
GB201012101D0 (en) Therapeutic agents
GB201010577D0 (en) Therapeutic agents
GB201010583D0 (en) Therapeutic agents
GB201003727D0 (en) Therapeutic agent
GB201021708D0 (en) Novel Therapeutic use
GB201004674D0 (en) Novel therapy
GB201110895D0 (en) Therapeutic use